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Abstract
Sharing of final research data from clinical research is an essential part of the scientific method. The U.S. National
Institutes of Health require some grant applications to include plans for sharing final research data, which it defines
as the factual materials necessary to document, support, and validate research findings. In the U.S., however, the
Privacy Rule adopted under the Health Insurance Portability and Accountability Act impedes the sharing of final
research data. In most situations, final research data may be shared only where all information that could possibly
be used to identify the subject has been deleted, or where the subject has given authorization for specific
research, or an Institutional Review Board has granted a waiver.
Introduction
For the original investigators in a clinical trial to share
their final research data with independent investigators
to permit them to build upon or reproduce the original
investigators’ conclusions is an essential part of the
scientific method [1]. The importance of sharing is
reflected by evidence that published reports from inves-
tigators who share their final research data have signifi-
cantly more citations compared to reports without
sharing [2]. In the U.S., the Privacy Rule [3] adopted
under the Health Insurance Portability and Accountabil-
ity Act of 1996 (HIPAA) [4], impedes the sharing of
final research data.
Discussion
Background
The sharing of final research data is a long-standing
issue, but it came to the forefront in February
2001when Nature and Science each published draft
sequences of the human genome [5,6]. The draft
sequence in Nature, which was the result of research by
the International Human Genome Sequence Consor-
tium, was deposited in GenBank, a publicly available
databank, but the sequence in Science,w h i c hr e s u l t e d
from a commercial enterprise, was deposited only in the
commercial enterprise’s website, with some restrictions
on access. As the U.S. National Research Council noted,
the restrictions on access to the sequence reported in
Science “provoked considerable debate in the life-
sciences communities” [7].
Despite this debate, Savage and Vickers, eight years
later, found that only one in ten of investigators who
published in two journals with “exceedingly” explicit
requirements for data sharing actually shared data in
response to a request from an independent investigator
[8]. This finding is consistent with survey research of
life scientists, which showed a perception that sharing of
data has become more problematic over the past two
decades [7].
The U.S. National Institutes of Health (NIH) have
adopted a formal data sharing policy [9], pursuant to
which the NIH requires applications for grants of more
than $500,000 in annual direct costs to include either a
plan for sharing final research data from the research
conducted under the grant, or an explanation of why
data sharing is “not possible.” In particular, NIH “recog-
nizes the need to protect patentable and other proprie-
tary data” in some circumstances. Reviewers of grant
applications do not consider the data sharing plan in
evaluating the scientific merit and priority of an applica-
tion. Instead, the NIH program staff addresses the Correspondence: jdmiller@jhsph.edu
Johns Hopkins Bloomberg School of Public Health, Department of Health
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data sharing is not possible.
In its data sharing policy, the NIH defines “final
research data” to mean the “recorded factual materials
commonly accepted in the scientific community as
necessary to document, support, and validate research
findings.” Final research data, according to NIH, “does
not mean summary statistics or tables; rather it means
the data on which summary statistics and tables are
based,” which usually will be a “computerized dataset.”
Therefore, final research data will not include case
report forms or other “clinical source documents.”
NIH apparently does not collect, or at least does not
make public, data on what proportion of its grants that
are subject to the data sharing policy actually result in
the sharing of final research data. Piwowar and Chapman,
[10] using a sample of published papers identified by
O c h s n e re ta l[ 1 1 ]t h a tr e p o r t e do nD N Am i c r o a r r a y
research, estimated that, of the papers that appeared to
be subject to the NIH data sharing policy (n = 61), only
52% referred in the published article to deposition of the
microarray dataset in a public depository or elsewhere.
While Piwowar and Chapman cautioned that their esti-
mates must be considered preliminary, they found it sur-
prising that the data sharing policy did not apply to a
greater proportion of the NIH funded studies in the
Ochsner sample. They suggested both expanding the
i n c l u s i o nc r i t e r i af o rt r i g g e r i n gt h ed a t as h a r i n gp o l i c y
and requiring researchers to cite an open-access database
accession number in their published papers and future
grant requests. These are valuable suggestions.
The Privacy Rule
The Privacy Rule is an administrative regulation adopted
by the U.S. Department of Health and Human Services
(HHS) pursuant to HIPAA. This regulation places strin-
gent and complex limits on the use and disclosure of
health information about individuals by many health
care providers. Since clinical trials typically take place as
part of the provision of health care to individuals, the
P r i v a c yR u l eh a sad i r e c ta n di m p o r t a n te f f e c to nt h e
sharing of clinical research data.
The Privacy Rule applies to “Protected Health Infor-
mation” (PHI), which is “individually identifiable health
information” that is “transmitted or maintained” in an
electronic media or “any other form or medium.” In the
Rule, “individually identifiable health information” is
defined to mean information created or received by a
health care provider (or certain other entities) that:
￿ relates to an individual’s health, or the provision of
health care to that individual, including demographic
information; and that
￿ could be used to identify the individual [12].
As an example, the information in the Case Report
Forms (CRF) used in many clinical trials might in some
circumstances constitute PHI.
A “covered entity” under the Privacy Rule “may not
use or disclose protected health information except as
permitted or required” by the Privacy Rule [13]. In the
Rule, a “covered entity” is defined to include a health
care provider “who transmits any health information in
electronic form” for certain standard transactions such
as claims and benefit eligibility inquiries [14]. (The defi-
nition of “covered entity” includes some entities other
than health care providers as well.) As a practical mat-
ter, most health care providers in the U.S. are “covered
entities” and thus subject to the Privacy Rule.
The Privacy Rule contains specific provisions governing
the use or disclosure of PHI by covered entities for the
purpose of research. A covered entity may conduct
research using PHI, or may disclose PHI to an investigator
for the purpose of research, in five situations, as follows:
￿ Where the individual who is the subject of the PHI
has authorized in writing the use of the PHI in spe-
cific research [15];
￿ Where the covered entity receives documentation
that an Institutional Review Board (IRB) has waived
the requirement of an authorization, or has approved
the alteration of an existing authorization [16], pro-
vided that the IRB meets the detailed standards set
forth in the Privacy Rule [17];
￿ Where the investigator represents to the covered
entity that the PHI will be used “solely” to prepare a
research protocol or for other purposes “preparatory
to research” (such as to aid in study recruitment);
that the PHI will not be removed from the covered
entity; and that the PHI is “necessary” for these
research purposes [18];
￿ Where the investigator represents to the covered
entity that the research is “solely” on the PHI of
decedents, and that the PHI is “necessary” for this
research [19];
￿ Finally, a covered entity may disclose for research
purposes a “limited data set” of PHI, with certain
“direct identifiers” excluded, provided that the cov-
ered entity obtains a “data use agreement” with the
investigator that the limited data set will be used or
disclosed “for limited purposes” [20].
In the context of clinical research, probably the most
common means of using and disclosing PHI is by means
of an authorization from each subject in the trial. HHS,
however, has interpreted the Privacy Rule to require that
authorizations for research be limited to specific research
that is described in the authorization. This interpretation
means that using PHI in future research requires the
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new authorization from each individual subject, either of
which is burdensome [21]. The Institute of Medicine,
among others, has criticized this interpretation by HHS on
the ground that in some circumstances it limits the shar-
ing of clinical data [22,23].
In July 2010, HHS issued a statement that it is consid-
ering revising its interpretation and requested comments
from interested parties [24]. HHS is considering several
alternatives, including that the future research be “ade-
quately described” in the authorization, or that the Priv-
a c yR u l eb ea m e n d e dt or e q u i r ea u t h o r i z a t i o n st o
contain specified statements concerning future research.
H H Ss h o u l da d o p tar e v i s e di n t e r p r e t a t i o nt h a tf o s t e r s
the sharing of data for future research.
’De-Identified’ Health Information
S i n c et h eP r i v a c yR u l ep r o t e c t sP H I ,n oa u t h o r i z a t i o n
from research subjects is required where PHI has been
‘de-identified’ as provided in the Privacy Rule so that it
is no longer PHI. Covered entities are specifically per-
mitted to use PHI to create de-identified information
that is no longer PHI and that accordingly may be freely
disclosed and shared [25].
The Privacy Rule permits covered entities to de-iden-
tify PHI in two alternative ways [26]. First, a covered
entity may have a statistician “with knowledge of meth-
ods for rendering information not individually identifi-
able” determine that the “risk is very small” that the
information could be used together with “other reason-
ably available information” to identify the individual
who is the subject of the de-identified information. This
method is used sometimes by commercial providers of
health informatics data.
Second, a covered entity may remove eighteen specific
identifiers listed in the Privacy Rule [27], provided that
the covered entity does not have “actual knowledge”
that the de-identified information still could be used to
identify an individual who is the subject of the informa-
tion. For purposes of sharing data from a clinical trial,
perhaps the most problematic of the eighteen specified
identifiers is that “[a]ll elements of dates, including birth
dates, admission date, discharge date, [and] date of
death” must be removed from the PHI. Hrynaszkiewicz
et al have proposed replacing each actual date with a
fictitious date derived by adding or subtracting a ran-
dom number of days from the actual date [28].
Enforcement of the Privacy Rule
HIPAA and the Privacy Rule do not grant private parties
a right to recover money damages from, or an injunc-
tion against, a covered entity. [29]. Until 2009, only
HHS had authority to enforce HIPAA, including the
Privacy Rule, but it tended to do so in administrative
proceedings, rather than through the courts. While HHS
retains its authority to seek monetary and criminal
penalties for HIPAA violations, in 2009 Congress gave
the Attorneys General of the States authority to enforce
HIPAA and the Privacy Rule by filing civil actions for
monetary penalties in federal court [30]. The early
experience with this new authority suggests that some
State Attorneys General will be aggressive in taking
action against covered entities that use or disclose PHI
in violation of the Privacy Rule, even when the use or
disclosure is plainly inadvertent [31].
The Privacy Rule does not replace (or ‘preempt’)S t a t e
laws that are more stringent than the Privacy Rule in
protecting individual health information [32,33]. Thus,
even an investigator who scrupulously complies with the
Privacy Rule could face litigation brought under State
law. An important example is the Havasupai Indian
Tribe claims against Arizona State University (ASU)
[34]. In 2004, the Tribe began a lawsuit against ASU in
which the Tribe alleged that researchers at ASU had
collected blood samples from members of the Tribe for
research into the genetic basis of diabetes but subse-
quently had used the blood samples in a wide range of
research, including migration, inbreeding and schizo-
p h r e n i at h a tw e r en o td i r e c t ly relevant to diabetes. In
addition, the Tribe alleged that the ASU researchers had
shared the blood samples with researchers at other insti-
tutions. The consent form signed by some members of
the Tribe in the early 1990’s stated that the blood sam-
p l e sw o u l db eu s e dt o“study the causes of behavioral/
medical disorders,” but the Tribe alleged that members
of the Tribe were told orally and in writing that the
research was on the potential genetic cause of diabetes,
which is prevalent among Tribal members [35]. The
research apparently was approved by the ASU Institu-
tional Review Board (IRB) in 1991, but the IRB subse-
quently, and routinely, discarded the records of its
approval of the research.
In its lawsuit, the Havasupai Tribe asserted various
claims, including fraud and invasion of privacy, under
Arizona state law [36].
In 2008, the Arizona Court of Appeals ruled in favor of
the Tribe on a technical legal issue, rather than on the
merits, but the court’s opinion appeared to recognize that
the Tribe might have a valid claim on the merits under
Arizona law [37]. ASU recently settled the litigation with
the Tribe in exchange for an apology and a payment of
$700,000 divided among 41 members of the Tribe [34].
Conclusion
HIPAA and the Privacy Rule impose stringent limita-
tions on the sharing of final research data that consti-
tute PHI. Even where individuals who participate as
subjects in clinical research sign written authorizations
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are valid only for the specific research described in the
authorization, not future research. While PHI may be
de-identified so that it is no longer PHI, and therefore
may be freely disclosed and shared, the requirement
that dates be deleted, and perhaps other required dele-
tions as well, may limit the value of de-identified data in
future research.
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